IPPS Final Rule Creates New DRG 525, Increases Reimbursement For LVADs
This article was originally published in The Gray Sheet
Executive Summary
Thoratec plans to work with the Centers for Medicare & Medicaid Services to further improve reimbursement levels for implantation of left ventricular assist devices as destination therapy
You may also be interested in...
Thoratec HeartMate Receives Long-Awaited Destination Therapy Indication
Thoratec will target major transplant and open-heart surgery centers in a new marketing initiative to promote the HeartMate SNAP-VE left ventricular assist device as a destination, "alternative-to-transplant" therapy for end-stage heart failure. FDA approved a PMA supplement for the indication on Nov. 6
Thoratec HeartMate Receives Long-Awaited Destination Therapy Indication
Thoratec will target major transplant and open-heart surgery centers in a new marketing initiative to promote the HeartMate SNAP-VE left ventricular assist device as a destination, "alternative-to-transplant" therapy for end-stage heart failure. FDA approved a PMA supplement for the indication on Nov. 6
Thoratec Makes Case For Permanent VAD Higher Medicare Reimbursement
Thoratec is expecting CMS to boost Medicare reimbursement for mechanical cardiac assist device implantation based on data showing that the firm's HeartMate XVE left ventricular assist device (LVAD) is a cost-effective destination therapy for end-stage heart failure patients